New hope for patients with Alzheimer's disease

A new therapy of Alzheimer's disease brings new hope for people to cure this incurable disease. This therapy seems to be able to reduce the major pathogenic factor protein deposits in the brains of patients. According to research published by American and Swiss researchers in the journal Nature, the researchers used recombinant human proteins to conduct research and found that the new treatment also slows down the decline of brain processes.

The researchers divided 165 patients with Alzheimer's disease into two groups to conduct research. A group of patients took placebo, and the other group took Aducanumab antibody once a month. Such antibodies can reduce the typical protein deposits in brains of patients with Alzheimer's disease. Before typical features of Alzheimer's disease such as memory loss, thought and language barriers occur, the brains of patients have deposited amyloid plaques. We can call them β-amyloid plaques.

After a year of observation, a group of patients showed significant reduce of protein deposits. Moreover, the decline rate of cognitive function in patients was significantly slower than patients who took placebo. But the researchers believed that the positive role of the new antibody on cognitive function needs further investigation. However, scientists' findings confirm the hypothesis of amyloid protein and correctness of continuing to study the antibody which treats Alzheimer's disease.

Alzheimer's disease specialist Christian Haass at Neurodegenerative Disease Center Germany (DZNE) said previous studies also found the possibility of removing brain protein deposits, but it can't restore lost memories or stable memory. In contrast, the biggest difference in this research result is that we can confirm that reducing the protein deposits and memory stability is closely related. This is of course the main goal we want to achieve.

Haas said that this is undoubtly a very great progress that has been ever made in this area. Because the results of this study clearly indicate that antibody therapy is effective for the treatment of Alzheimer's disease. Antibody therapy can maintain memory. Haas believes, however, it is too early to refer it as "breakthrough". This is a small-scale test, but it is definitely the first to have some positive impacts on the memory of Alzheimer's patients at least.

Previous multiple tests showed that Alzheimer's disease has already develops long before memory loss, because protein deposits have been formed at an earlier time. Patients must be treated early if they want to prevent progression of the disease. It will be too late for most patients if they go to the doctor when the memory is fading. Flarebio provides you with good-quality recombinant proteins such as recombinant ITGB2 at good prices.